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Abstract: Angiotensin converting enzyme
(ACE) inhibitors have been known to inhibit
the effects of angiotensin II which increases
the vascular resistance. In this study, we
studied the acute effects of a single dose of
2.5 mg oral cilazapril, ACE inhibitor on blood
flow velocity and vascular resistance
parameters of central retinal artery (CRA) by
color Doppler ultrasonography in 17 patients
with nonproliferative diabetic retinopathy
(NPDR) and compared the effects of the
drug with a placebo group including 17
patients with nonproliferative diabetic
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retinopathy. After cilazapril medication, peak
systolic blood flow velocity of central retinal
artery didn't change, while peak diastolic and
mean blood flow velocity increased (p<0.05,
p<0.05). Significant decrease in pulsatility
and resistivity indices of the vessel were
observed (p<0.05, p<0.05). Cilazapril
decreases the resistance parameters of CRA
which nourishes one of the target tissues of
diabetic retinopathy.

Key Words: Central retinal artery, diabetes
retinopathy, cilazapril, color Doppler imaging.

Impaired autoregulation of the retinal vasculature,
alteration in retinal blood flow and breakdown of the
blood-retinal barrier are the certain physiologic
abnormalities that have been identified during the early
course of diabetic retinopathy (1).

(5). Recent evidence suggests that besides this circulating
renin-angiotensin system (RAS), there also exist tissue or
local renin-renin-angiotensin systems (5-7). Local
angiotensin production may therfore occur indepently of
the reaction of circulating renin with circulating renin
substrate (5-7).

The investigation of retinal blood flow and its
regulation in diabetic retinopathy is of primary
importance as it may lead better understanding of
pathophysiology of the disease (2). Furthermore, it may
help the assesment of different treatment modalities and
in the monitorization of the progression (3). Color
Doppler ultrasonograpy is a noninvasive and simple
method which has recently become available for detecting
the localisation of vessels and obtaining the data about
blood flow velocities and vascular resistance indices (4).

Studies in bovine eyes showed that both renin and
prorenin were present in all segments of the eye (8).
Moreover, using the polymerase chain reaction, Wagner
et al. were able to show expression of the renin-, renin
substrate-, and ACE-genes in human ocular tissue (9).
The presence of ACE in the eye has been shown as well,
not only in the retina, choroid and ciliary body, but also in
aqueous fluid (5,10,11). Taken together, these findins
suggest that the eye has its own RAS and that it is
activated in eyes affected by diabetic retinopathy (5).

According to the classical concept, angiotensin I (A I)
and angiotensin II (A II) are generated within the
circulation by sequential cleavage of liver derived renin
substrate. Renin, synthesized in the kidney, cleaves this
substrate to form A I. Angiotensin converting enzyme
(ACE) converts A I to A II, a potent vasoconstrictor and a
stimulant of the release of aldosterone from the adrenal

Chronic administration of ACE inhibitors is shown to
regress the vascular deterioration especially in
hypertensives and to have the ability of increasing blood
flow velocities after non-selectively decreasing the
vascular resistance in various tissues (12). Among the
ACE inhibitors cilazapril is a prodrug being converted to
its active form cilazaprilat. It is rapidly absorbed with
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peak plasma levels which is reached within one to two
hours and continues down for eight hours (7).
In this report, the acute effects of cilazapril on blood
flow and vascular resistance parameters of CRA has been
studied in patiens with nonproliferative diabetic
retinopathy.
Material and Methods
In this study, thirty four patients with type II diabetes
mellitus followed for NPDR were included. The hospital
ethic committee approved the study. Informed consent
was obtained from each subject. The prestudy ocular
examination of either eye of the patients was as follows;
Snellen's visual acuity measurement, anterior segment
examination by slit lamb biomicroscopy, applanation
tonometry and fundoscopy by Goldman three mirror
contact lens and fundus florescein angiography. The
prestudy systemic examination of each patient performed
by an internist included medical history, heart rate and
blood pressure measurements, urinalysis, blood
chemistry studies and complete blood cell counts. After
systemic and ocular examinations, patients having
systemic or ocular pathology other than diabetes mellitus
and taking any medication other than oral hypoglycemic
agents were excluded. Thirty-four diabetic patients whose
metabolic control was accomplished with diet and oral
hypoglycemic agents were randomly assigned to form
group I and group II each including 17 subjects. The eyes
of the patients with better visual acuity were selected for
the study. The physicians performing the blood pressure
and color Doppler ultrasonographic measurements were
unaware of the patient's assignment.
On the study days, between 9: 00 and 10: 00 AM, the
resting average brachial arterial blood pressure of the
patients in two groups was calculated by using the blood
pressure readings from two arms. Then the patients were
put in a supine position and ultrasound conductive gel
was applied to the external surface of the eye lids. Care
was taken to exert as little transducer pressure as
possible on the closed eye lids. An ATL Ultramark 9
Duplex Scanner (Advanced Technical LaboratoriesScientific Medical Systems Co, Bothell. Wash) with a 5
MHz probe was used to display the vessel using vascular
mode. To examine central retinal artery (CRA), B mode
image of the optic nerve was used as a landmark for the
identification of the vessel. The angle between the vessel
and the sound beam under this circumstance could be
easily kept below 20 degrees. The colors can arbitrarily
assigned but in this study flow toward the transducer
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(artery) depicted as red and away from the transducer
(vein) as blue. A Doppler gate of 1.5x1.5 mm was
directed toward the vessel. The signal coming from CRA
can be easily seperated from the signal coming from
central retinal vein because of the directional nature of
the Doppler signals and the characteristic waveform
differences in spectral analysis. To avoid the inclusion of
short ciliary arteries into the central retinal artery sample
volume, the tracing of the central retinal artery was
evaluated only if flow waveforms coming from CRA and
central retinal vein could be recorded simultaneously. A
reading was taken only when three consecutive pulse
waveforms were obtainable from the artery. After
spectral analysis was performed to obtain positive
waveform for the arterial flow, peak systolic flow velocity
(PS; cm/sec), peak diastolic flow velocity (PD; cm/sec)
and mean flow velocity (M; cm/sec) for CRA were
determined by averaging the readings from three
waveforms. Similarly the pulsatility index (PI) and
resistive index (RI) which were the vascular resistance
parameters for CRA were calculated by using the formula
below;
PI=PS-PD/M

RI=PS-PD/PD

After performing color Doppler utrasonographic
examination for two groups, a single dose of 2.5 mg oral
cilazapril was administered for the patients in group I
and the patients in group II received placebo (vehicle).
Three hours after medications, systemic blood pressure
measurement and color Doppler ultrasonographic
examination were reperformed in both groups.
The results are expressed as the mean value.
Differences taking place after medications in systemic
blood pressure, blood flow velocity and vascular
resistance parameters of CRA are compared with baseline
values in both groups by Wilcoxon rank-sum test. Results
were considered statistically significant at p<0.05.
Results
Group I included 8 males and 9 females while there
were 10 males and 7 females in group II. Group I and
group II were similar with respect to age, diabetic
duration and fasting blood glucose level (Table 1). Group
I and II each included 17 eyes with NPDR.
The systolic and diastolic blood pressure values of the
two groups before and after cilazapril or placebo
administrations are shown in Table 2. After cilazapril
medication the mean systolic and diastolic blood pressures
of the patients in group I showed significant decrease
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Group (mean±SD)

Age (year)
Diabetic duration (year)

Group II

Group I

(n=17)

(n=17)

53.6±12.4

54.2±13.3

9.3±8.2

9.2±8.4

125.7±20.3

129.2±17.4

Table 1.

Features of patients in group I and II.

Table 2.

Systolic and diastolic blood
pressures and flow velocity and
resistance parameters of central
retinal artery of the patients

Fasting blood glucose level
(mg/dl)

Group I: cilazapril, Group II: placebo
Group (mean±SD)

Parameters

Group II

Group I

(n=17)

(n=17)

Baseline

th

3

hour

Baseline

3th hour

126.6±13.8

117.4±12.5*

Systolic blood pressure
(mmHg)

127.3±14.4 125.1±13.2

Diastolic blood pressure
(mmHg)

83.4±8.6

82.8±8.4

85.5±7.3

78.6±6.4*

7.9±1.9

7.9±1.9

7.9±2.0

8.0±1.8

2.7±0.5

2.7±0.5

2.7±0.7

3.2±0.7*

(cm/sec)

4.5±1.3

4.5±1.1

4.6±1.1

5.0±1.1*

Pulsatility Index

1.1±0.2

1.1±0.2

1.1±0.2

1.0 ±0.2*

Resistive Index

0.7±0.1

0.7±0.1

0.7±0.1

0.6±0.0*

Peak systolic flow velocity
(cm/sec)
Peak diastolic flow velocity
(cm/sec)
Mean flow velocity

Group I: cilazapril, Group II: placebo, * p<0.05, 3

th

hour vs. baseline

compared with group II (p<0.05). We observed no
significant change in systemic blood pressure after
placebo administration in group II.
Blood flow velocity and vascular resistance
parameters of CRA before and after cilazapril or placebo
administrations are shown in Table 2. We didn't observe
any significant change in blood flow velocity and
resistance parameters of CRA after placebo

administration in group II. After cilazapril medication PS
value of CRA showed insignificant increase while PD and
M values were significantly higher compared with placebo
(p<0.05 and p<0.05, respectively). PI and RI values of
CRA showed significant decrease after cilazapril
administration in group I compared with group II
(p<0.05 and p<0.05, respectively).
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Discussion
Diabetic retinopathy is the most frequent cause of
blindness among the world. However, the
pathophysiology involved in the development of visual
damage in this disease is totally unknown.
The function of an ocular RAS is not yet clear. A II may
regulate intraocular vascular tone and aqueous fluid
hemodynamics (13,14). In addition, A II has trophic and
mitogenic actions on vascular smooth muscle and other
cells (15,16). Danser et al. found prorenin to be increased
in vitreus fluid from patients with proliferative diabetic
retinopathy, suggesting that an activated intraocular RAS
may be involved in the development of this type of
retinopathy (17). Its activation in the eyes of diabetic
subjects with proliferative retinopathy may suggest that A
II is involved in the development of neovascularization, as
has been shown by other (18).
There is no doubt that ACE inhibitors have multiple
sites of action on the circulation. The chief and the best
understood mechanism is inhibition of the RAS not only
of the circulating components but very probably also
those found in the various tissues, particularly the
vascular bed (7). It has been suggested that ACE inhibitor
therapy decrease arterial calcium contents (19). Cilazapril
as an ACE inhibitor has also been suggested to reduce the
vascular resistance in every organ of hypertensive rats
besides its regional blood flow increasing effect in most of
the organs (12, 20).
We observed insignificant increase in peak systolic
flow velocity while mean and peak diastolic flow velocities
of CRA were found significantly higher at the third hour

of cilazapril administration compared with the placebo
group. Furthermore, there was a significant decrease in
the vascular resistance parameters of CRA in cilazapril
group compared with the placebo group. These changes
have been thought to be consistent with the significant
increase in peak diastolic flow velocity.
The decrease in the vascular resistance of CRA after
cilazapril administration in group I patients compared
with group II made us think that whether the blood
flow in the retina might be affected from the decrease
taking place in resistance parameters of CRA. However,
the possible changes taking place in the circulation of
retinal tissue couldn't be measured by color Doppler
ultrasonography.
Strocchi et al. reported that enalapril, one of the ACE
inhibitors, improved regional hemodynamics in patients
with Type II diabetes mellitus (21). We observed similar
effects on CRA in diabetic subjects. This improvement in
vascular resistance of CRA might be related with the
systemic hemodynamic effect of cilazapril as confirmed by
the decreasing systemic arterial blood pressure after
medication, but indeed it might be related with the
inhibition of possibly existing local RAS in or around CRA.
In conclusion; significant decrease caused by an ACE
inhibitor in the vascular resistance of the main artery,
namely the central retinal artery which nourishes the
target tissue of diabetes retinopathy might cause an
improvement in the retinal oxygenation as well, therefore
further investigation should be warranted to ascertain the
possible effect of an ACE inhibitor on retinal tissue
circulation (4,5).
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